MEDICAMEN Biotech Limited (MBL) is committed to providing quality medicines at an affordable cost through relentless pursuit of excellence in its operations, product quality, documentation and service.
Committed to providing solutions to the pharmaceutical industry across the value chain Over the last decade, Medicamen has emerged as an integrated Pharmaceutical and Life Sciences Solution Provider offering products & services to its customers across the world.
Cancer care refers to the medical treatment, management, and support provided to individuals diagnosed with cancer.
Cardiology is the branch of medicine that deals with the diagnosis and treatment of heart-related diseases and disorders.
CNS (Central Nervous System): The CNS is a crucial part of the nervous system that includes the brain and spinal cord.
Diabetology is the specialized field of medicine that focuses on the study, diagnosis, and management of diabetes mellitus.
Anti-malarials are drugs used to prevent and treat malaria, a mosquito-borne infectious disease caused by Plasmodium parasites.
Vitamins are organic compounds that are essential for the proper functioning of the body. They play crucial roles in various ...
Antibiotics are a class of medications used to treat bacterial infections. They work by killing or inhibiting the growth of bacteria...
Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage.
MEDICAMEN BIOTECH LTD. announced that Shivalik Rasayan Ltd., which is the parent company of Medicamen, has successfully got USFDA Approval for its state of the art global API manufacturing facility.
Medicamen Biotech is proud to announce that its state-of-the-art manufacturing facility in Bhiwadi, Rajasthan, has achieved European Union Good Manufacturing Practice (EU GMP) certification from the National Organisation for Medicines in Athens, Greece.
We’re excited to announce that our Sterile Oncology Facility is now USFDA approved, enabling us to expand into regulated markets like the US and the Middle East. This milestone reflects our commitment to delivering high-quality oncology treatments globally, supporting patients with advanced, compliant options.
In April 2023, the Oncology Plant located in Haridwar underwent a comprehensive audit by the US Food and Drug Administration (USFDA). This successful audit positions the facility for potential approvals in regulated markets, including the United States and the Middle East.
“This is major milestone for the Company which will trigger USFDA Audit in due course of time” said Medicamen. For the quarter ended March, the company reported a 20 percent year-on-year increase in revenue to Rs 138 crore in FY23 as against the previous year.
Medicamen Biotech के शेयरों में आज 19 जुलाई को 6 फीसदी से अधिक की रैली देखी गई। इस समय यह स्टॉक NSE पर 6.68 फीसदी की बढ़त के साथ 768 रुपये के भाव पर ट्रेड कर रहा है। दरअसल, Medicamen ने US फूड एंड ड्रग एडमिनिस्ट्रेशन (USFDA) के साथ BORTEZOMIB इंजेक्शन के लिए अपना पहला Abbreviated न्यूज ड्रग एप्लिकेशन (ANDA) दायर किया है।
Medicamen Lifesciences, a subsidiary of MEDICAMEN BIOTECH, officially launched operations in 2022. The company specializes in the manufacturing and marketing of pharmaceutical products, with a focus on Anti-hypertensives, Antidiabetics, and Cardiology treatments.
MEDICAMEN has officially initiated domestic oncology marketing, aimed at raising awareness and promoting its range of oncology products. This strategy is designed to enhance the visibility of the company’s offerings in the oncology sector and to engage healthcare professionals and patients effectively.
The company has made significant strides in regulatory compliance by filing Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA) and Certificates of Suitability (CEPs) with the European Directorate for the Quality of Medicines (EDQM) for its Active Pharmaceutical Ingredients (APIs).
The Haridwar Formulation Unit II, specializing in Finished Dosage Forms (FDF) for oncology, has officially begun operations. This new facility is set to enhance the production of critical oncology medications, reinforcing the company's commitment to providing high-quality pharmaceutical solutions for cancer treatment.
"MEDICAMEN HAS EMBARKED UPON A NEW AND EXCITING PHASE OF ITS GROWTH JOURNEY. MEDICAMEN HAS PROVED ITS TECHNICAL EXCELLENCE BY DEVELOPING COMPLEX AND CHALLENGING FORMULATION TECHNOLOGIES. WE ARE COMMITTED TO THE PURSUIT OF EXCELLENCE IN BUSINESS AND SOCIETY."
- RAHUL BISHNOI Chairman, Medicamen Biotech
We are optimistic about receiving USFDA approval for our Oncology Plant, which will unlock opportunities in regulated markets, particularly in the US and Middle East.
Medicamen Biotech’s Bhiwadi Manufacturing Facility Achieves European Union GMP Approval from MOH, Greece. Our state-of-the-art manufacturing facility at Bhiwadi, Rajasthan, is now EU GMP certified by the National Organisation for Medicines, Athens - Greece!
Shivalik Rasayan Ltd., which is the parent company of Medicamen Biotech Ltd., has successfully got USFDA Approval for its state of the art global API manufacturing facility.
Copyright © 2023, MEDICAMEN BIOTECH LIMITED. All Rights Reserved. Designed by Rautela Tech